Welcome to The Biotherapy Development Association
The Biotherapy Development Association (BDA) is a global cooperative group whose primary focus is to develop targeted cancer therapies using biological agents.

It is based in Europe and interacts with the US, Japan and South-east Asia. Our head office is in Munich, Germany, and the association is registered under German Law.

Our Aims
To allow efficient and rapid drug development from pre-clinical stage to clinical stage by conducting pre-clinical studies and GCP-compliant phase I/II clinical studies to identify toxicity profiles, the optimal biologically active dose and clinical response.

• To interact with various partners with the aim of progressing new attractive drugs and concepts through clinical development to registration.
• To provide an effective interface with regulatory authorities in Europe, the US and Sout-east Asia.
• To give advice on the development of biotherapies to pharmaceutical and biotechnology companies and the non-expert medical community

Our members are experienced researchers and investigators in the development of biological agents for the treatment of cancer with, for example:

• Monoclonal Antibodies
• Signal Transduction Inhibitors
• Anti-Angiogenic Therapies
• Immunomodulators
• Cancer Vaccines
• Gene Therapy
• Definition and Validation of Biomarkers

In addition the group also has a strong interest in the identification and application of appropriate biomarkers to enhance and accelerate the clinical trials process in oncology.